ProteoSys AG innovation in functional proteomics
home contact technology fee for
company publications cooperation
Current cooperations
Former cooperations
International cooperations

Since its beginning, ProteoSys has been actively involved in cooperative projects with both academic and industrial partners. Because of its distinguished expertise, we participated in collaborative projects of the Framework Programmes of the European Commission (FP5-FP7) in different fields (e.g., cancer, ageing, rare and infectious diseases, toxicology, neurodegenerative diseases) and dealt with various kinds of models (stem cells, mouse, rat, fungi, HUVEC) and samples (tissue, blood, urine).

Publicly funded projects are an important pillar in our strategy. Cooperative activities with academic institutions, other SMEs and large companies have contributed to the development and the focus of our technologies and research paradigms.

ProteoSys cooperates and cooperated in the following projects :

ESNATS - Embryonic Stem cell-based Novel Alternative Testing Strategies (FP7)

The aim of the ESNATS project is to develop a novel “all-in-one” toxicity test platform based on embryonic stem cells (ESCs), in particular human ESCs, to accelerate drug development, reduce R&D costs and propose a powerful alternative to animal tests in the spirit of the "Three R principle".

NeuroCypres - Neurotransmitter Cys-loop receptors: structure, function and disease (FP7)

Neurocypres is a large-scale integrated project involving 20 European laboratories in the area of Cys-loop neurotransmitter receptors. In the seventh research framework programme (FP7), the EU commission devoted a special call to stimulate high-throughput approaches to structure function analyses of membrane-transporters and channels for the identification of potential new drug target sites. The NeuroCypres consortium is devoted to studying structural and functional aspects of Cys-loop receptors, a superfamily of ligand-gated ion channels.

FIGHT-MG - Myasthenias, a group of immune mediated neurological diseases: from etiology to therapy (FP7)

Myasthenia Gravis (MG) is a heterogeneous rare autoimmune neurological disease affecting the neuromuscular junction (NMJ). FIGHT-MG addresses the natural course of the disease and its aetiology. It also studies pathogenic mechanisms at the NMJ in MG patients and experimental models, and evaluates the capacity of muscle cell satellites from patients to regenerate muscle and form new endplates in immunodeficient mice. Finally it will look for new diagnostic and monitoring assays.

DNT in vitro - Development of predictive in vitro tests on toxicological safety tests for development neurotoxicity (Entwicklung von prädiktiven in vitro Tests zur sicherheitstoxikologischen Prüfung auf entwicklungsbedingte Neurotoxizität) (bmbf)

Prediction of developmental neurotoxic effects is a key feature in the toxicological profile of a compound. This situation will considerably increase the number of laboratory animals. Validated alternative methods for developmental neurotoxicity testing are not available. Thus, standardised, predictive screens for the evaluation of developmental neurotoxicity need to be available with the ultimate goal of increased efficiency in terms of reduced animal use and higher throughput compared to whole-animal testing using the existing guidelines. The final goal of this research proposal is to develop standardised predictive cell-based in vitro assays for developmental neurotoxicity testing. Different complementary cell models which represent selected developmental stages of the developing brain in vivo will be investigated to predict developmental neurotoxicity in vivo from in vitro data.

 • Esnats

 • NeuroCypres

 • Fight-MG